Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CIBC World Keeps 'Sector Outperform' on Amgen

CIBC World reiterates sector outperform on Amgen (AMGN).

Analyst Matt Geller views a report in Saturday's New York Times as highly positive for Amgen. He notes the newspaper reported that European Union regulators are considering banning Johnson & Johnson's Eprex, its drug for chronic kidney failure. He says about $700 million of Eprex is sold in Europe for chronic kidney failure.

However, Geller notes Eprex has caused 160 cases of pure red cell aplasia, a blood disorder, and says a decision could come in days or weeks. If banned, these patients would probably switch to Amgen's Aranesp or Roche's NeoRecormon, both of which are sold in Europe for the same indication.

Geller maintains his $1.35 earnings per share estimate for 2002 $1.63 estimate for 2003. He has a $57 12 to 18 month target.

blog comments powered by Disqus